Tumor-Targeting Properties of Novel Antibodies Specific to the Large Isoform of Tenascin-C

Abstract

These data suggest that the F16 antibody, specific to domain A1 of tenascin-C, is a promising building block for the development of antibody-based pharmaceuticals in view of its excellent tumor-targeting performance and the strong expression of the antigen in a variety of primary and metastatic tumors.